) vaccines division, Sanofi Pasteur, recently announced that the
data from the pivotal trial of Menactra (meningococcal groups A,
C, Y and W-135 polysaccharide diphtheria toxoid conjugate
vaccine) has been published by the
Pediatric Infectious Disease Journal
GLAXOSMITHKLINE (GSK): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
In the trial, Menactra demonstrated a promising efficacy profile
as two-dose vaccine for infants and toddlers aged between 9
months and 23 months. It was observed that the use of Menactra
provided protection against four clinically meningococcal
We note that the Food and Drug Administration used data from the
above mentioned pivotal trial to approve Menactra in April 2011.
Menactra was first approved in 2005 as meningococcal conjugate
vaccine for people aged between 11 years and 55 years. In
subsequent years, the product's label was expanded to include
infants above 9 months.
In the third quarter of 2012, Menactra generated sales of €208
million accounting for approximately 14% of total vaccines sales
at Sanofi. In the US, Menactra sales inched up 0.6% to €195
Meningococcal disease, which includes meningitis, is estimated to
affect about 800 to 1,200 people in the US annually. About 10% of
the affected people could die and survivors could be afflicted by
permanent disabilities like hearing loss, neurological damage and
limb amputations. Currently, approved vaccines for meningococcal
) MenHibrix (meningococcal groups C and Y and haemophilus b
tetanus toxoid conjugate vaccine).
We are pleased with the company's efforts to develop its
pipeline. We expect Sanofi to continue to contain operating costs
in order to increase earnings in the face of weakening sales of
some of its biggest products. We also expect the company to
pursue bolt-on acquisitions.